eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Cetuximab and/or bevacizumab combined with combination chemotherapy in treating patients with metastatic colorectal cancer

eagle-i ID


Resource Type

  1. Clinical trial


  1. ClinicalTrials.gov url
  2. Intervention
    Antineoplastic combined chemotherapy
  3. Intervention
  4. Intervention
  5. Resource Description
    This randomized phase III trial is studying cetuximab and/or bevacizumab when given together with combination chemotherapy to compare how well they work in treating patients with metastatic colorectal cancer.
  6. Additional Name
    Phase III trial of irinotecan / 5-Fu / leucovorin or oxaliplatin / 5-Fu/ leucovorin with bevacizumab, or cetuximab (C225), or with the combination of bevacizumab and cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum
  7. Contact
    Berenberg, Jeffrey
  8. PI
    Berenberg, Jeffrey
  9. Topic
    colorectal cancer
  10. Study Population
    Males and females at least 18 years old with no CNS metastases, no previous bevacizumab or cetuximab, and at least 4 weeks since radiation therapy or surgery.
  11. Website(s)
  12. Website(s)
  13. Funded by
    Cancer Trials Support Unit
  14. Phase
    Phase 3 clinical trial
  15. Performed by
    Clinical Protocol & Data Management Shared Resource
Provenance Metadata About This Resource Record
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016